Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies.

Naing A, Cohen R, Dy GK, Hong DS, Dyster L, Hangauer DG, Kwan R, Fetterly G, Kurzrock R, Adjei AA.

Invest New Drugs. 2013 Aug;31(4):967-73. doi: 10.1007/s10637-013-9929-8. Epub 2013 Jan 30.

PMID:
23361621
2.

A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.

Antonarakis ES, Heath EI, Posadas EM, Yu EY, Harrison MR, Bruce JY, Cho SY, Wilding GE, Fetterly GJ, Hangauer DG, Kwan MF, Dyster LM, Carducci MA.

Cancer Chemother Pharmacol. 2013 Apr;71(4):883-92. doi: 10.1007/s00280-013-2079-z. Epub 2013 Jan 13.

3.

Detection of Bordetella pertussis in clinical specimens by PCR and a microtiter plate-based DNA hybridization assay.

Nelson S, Matlow A, McDowell C, Roscoe M, Karmali M, Penn L, Dyster L.

J Clin Microbiol. 1997 Jan;35(1):117-20.

4.

Microplate-based DNA hybridization assays for detection of human retroviral gene sequences.

Dyster LM, Abbott L, Bryz-Gornia V, Poiesz BJ, Papsidero LD.

J Clin Microbiol. 1994 Feb;32(2):547-50.

5.

Intragenic and intergenic recombination between temperature-sensitive mutants of vaccinia virus.

Fathi Z, Dyster LM, Seto J, Condit RC, Niles EG.

J Gen Virol. 1991 Nov;72 ( Pt 11):2733-7.

PMID:
1940868
6.

Supplemental Content

Loading ...
Support Center